AJANTA PHARMA LTD. Q2 FY26 Results

Summary

Ajanta Pharma Ltd., a specialty pharmaceutical formulation company, reported an excellent performance for the second quarter and half year ended 30 September 2025. The company's Profit after Tax (PAT) increased by 20% compared to the same period last year. The Board of Directors approved a first interim dividend of Rs. 28 per share for face value of Rs. 2 per share, amounting to Rs. 350 cr. The company's revenue from operations, EBITDA, and PAT showed significant growth in both Q2 FY 2026 and H1 FY 2026.

Key Highlights

1. 1

   Revenue from operations at Rs. 1,354 cr. against Rs. 1,187 cr.; up 14%

2. 2

   EBITDA at Rs. 328 cr. against Rs. 311 cr.; EBITDA at 24%; up 5%

3. 3

   Profit after tax at Rs. 260 cr. against Rs. 216 cr.; PAT at 19%; up 20%

4. 4

   Revenue from operations at Rs. 2,656 cr. against Rs. 2,332 cr.; up 14%

5. 5

   EBITDA at Rs. 679 cr. against Rs. 642 cr.; EBITDA at 26%; up 6%

6. 6

   Profit after tax at Rs. 516 cr. against Rs. 462 cr.; PAT at 19%; up 12%

7. 7

   ROCE stood at a healthy level of 30% and RONW at 25%

8. 8

   India branded generic performance exceeded IPM growth by 32%

9. 9

   Higher growth came from Volumes increase, which exceeded IPM by 115% & New launches, which exceeded IPM by 39%